Skip to main content
SpringerLink
Log in

Hepatitis Virus Resistance

  • Chapter
Antimicrobial Resistance and Implications for the Twenty-First Century

Part of the book series: Emerging Infectious Diseases of the 21 Century ((EIDC))

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • NIH Consensus Development Program, (2002), National Institutes of Health Consensus Development Conference Statement: management of hepatitis C: 2002-June 10–12, 2002. Hepatology, 36, S3–S20.

    Google Scholar 

  • Allen, M.I., Deslauriers, M., Andrews, C.W., Tipples, G.A., Walters, K.A., Tyrrell, D.L., Brown, N. and Condreay, L.D., (1998), Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Hepatology, 27, 1670–1677.

    PubMed  CAS  Google Scholar 

  • Angus, P., Vaughan, R., Xiong, S., Yang, H., Delaney, W., Gibbs, C., Brosgart, C., Colledge, D., Edwards, R., Ayres, A., Bartholomeusz, A. and Locarnini, S., (2003), Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology, 125, 292–297.

    PubMed  Google Scholar 

  • Bartenschlager, R., Frese, M. and Pietschmann, T., (2004), Novel insights into hepatitis C virus replication and persistence. Adv Virus Res, 63, 71–180.

    PubMed  CAS  Google Scholar 

  • Blindenbacher, A., Duong, F.H., Hunziker, L., Stutvoet, S.T., Wang, X., Terracciano, L., Moradpour, D., Blum, H.E., Alonzi, T., Tripodi, M., La Monica, N. and Heim, M.H., (2003), Expression of hepatitis C virus proteins inhibits interferon alpha signaling in the liver of transgenic mice. Gastroenterology, 124, 1465–1475.

    PubMed  CAS  Google Scholar 

  • Bozdayi, A.M., Uzunalimoglu, O., Turkyilmaz, A.R., Aslan, N., Sezgin, O., Sahin, T., Bozdayi, G., Cinar, K., Pai, S.B., Pai, R., Bozkaya, H., Karayalcin, S., Yurdaydin, C. and Schinazi, R.F., (2003), YSDD: a novel mutation in HBV DNA polymerase confers clinical resistance to lamivudine. J Viral Hepat, 10, 256–265.

    PubMed  CAS  Google Scholar 

  • Bronowicki, J.P., Ouzan, D., Asselah, T., Desmorat, H., Zarski, J.P., Foucher, J., Bourliere, M., Renou, C., Tran, A., Melin, P., Hezode, C., Chevalier, M., Bouvier-Alias, M., Chevaliez, S., Montestruc, F., Lonjon-Domanec, I. and Pawlotsky, J.M., (2006), Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alfa-2a plus ribavirin. Gastroenterology, 131, 1040–1048.

    PubMed  CAS  Google Scholar 

  • Buckheit, R.W., Jr., (2004), Understanding HIV resistance, fitness, replication capacity and compensation: targeting viral fitness as a therapeutic strategy. Expert Opin Investig Drugs, 13, 933–958.

    PubMed  CAS  Google Scholar 

  • Cane, P.A., Mutimer, D., Ratcliffe, D., Cook, P., Beards, G., Elias, E. and Pillay, D., (1999), Analysis of hepatitis B virus quasispecies changes during emergence and reversion of lamivudine resistance in liver transplantation. Antivir Ther, 4, 7–14.

    PubMed  CAS  Google Scholar 

  • Carroll, S.S. and Olsen, D.B., (2006), Nucleoside analog inhibitors of hepatitis C virus replication. Infect Disord Drug Targets, 6, 17–29.

    PubMed  CAS  Google Scholar 

  • Castera, L. and Pawlotsky, J.M., (2005), Noninvasive diagnosis of liver fibrosis in patients with chronic hepatitis C. MedGenMed, 7, 39.

    PubMed  Google Scholar 

  • Castera, L., Vergniol, J., Foucher, J., Le Bail, B., Chanteloup, E., Haaser, M., Darriet, M., Couzigou, P. and De Ledinghen, V., (2005), Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology, 128, 343–350.

    PubMed  Google Scholar 

  • Castet, V., Fournier, C., Soulier, A., Brillet, R., Coste, J., Larrey, D., Dhumeaux, D., Maurel, P. and Pawlotsky, J.M., (2002), Alpha interferon inhibits hepatitis C virus replication in primary human hepatocytes infected in vitro. J Virol, 76, 8189–8199.

    PubMed  CAS  Google Scholar 

  • Chang, T.T., Gish, R.G., de Man, R., Gadano, A., Sollano, J., Chao, Y.C., Lok, A.S., Han, K.H., Goodman, Z., Zhu, J., Cross, A., DeHertogh, D., Wilber, R., Colonno, R. and Apelian, D., (2006), A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med, 354, 1001–1010.

    PubMed  CAS  Google Scholar 

  • Chevaliez, S., Brillet, R., Hezode, C., Dhumeaux, D. and Pawlotsky, J.M., (2005), Assessment of ribavirin mutagenic properties in vivo and the influence of interferon alpha-induced reduction of hepatitis C virus RNA load upon therapy. Hepatology, 42 (Suppl. 1), 679A.

    Google Scholar 

  • Chin, R., Shaw, T., Torresi, J., Sozzi, V., Trautwein, C., Bock, T., Manns, M., Isom, H., Furman, P. and Locarnini, S., (2001), In vitro susceptibilities of wild-type or drug-resistant hepatitis B virus to (–)-beta-D-2,6-diaminopurine dioxolane and 2’-fluoro-5-methyl-beta-L-arabinofuranosyluracil. Antimicrob Agents Chemother, 45, 2495–2501.

    PubMed  CAS  Google Scholar 

  • Chong, Y., Stuyver, L., Otto, M.J., Schinazi, R.F. and Chu, C.K., (2003), Mechanism of antiviral activities of 3’-substituted l-nucleosides against 3TC-resistant HBV polymerase: a molecular modelling approach. Antivir Chem Chemother, 14, 309–319.

    PubMed  CAS  Google Scholar 

  • Clavel, F. and Hance, A.J., (2004), HIV drug resistance. N Engl J Med, 350, 1023–1035.

    PubMed  CAS  Google Scholar 

  • Colonno, R.J., Rose, R.E., Baldick, C.J., Levine, S.M., Klesczewski, K. and Tenney, D.J., (2006a), High barrier to resistance results in no emergence of entecavir resistance in nucleoside-naïve subjects during the first two years of therapy. J Hepatol, 44 (Suppl. 2), S182.

    Google Scholar 

  • Colonno, R.J., Rose, R.E., Pokornowski, K., Baldick, C.J., Klesczewski, K. and Tenney, D.J., (2006b), Assessment at three years shows high barrier to resistance is maintained in entecavir-treated nucleoside naive patients while resistance emergence increases over time in lamivudine refractory patients. Hepatology, 44 (Suppl. 2), 229A.

    Google Scholar 

  • Crotty, S., Cameron, C.E. and Andino, R., (2001), RNA virus error catastrophe: direct molecular test by using ribavirin. Proc Natl Acad Sci USA, 98, 6895–6900.

    PubMed  CAS  Google Scholar 

  • Crotty, S., Maag, D., Arnold, J.J., Zhong, W., Lau, J.Y., Hong, Z., Andino, R. and Cameron, C.E., (2000), The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen. Nat Med, 6, 1375–1379.

    PubMed  CAS  Google Scholar 

  • Das, K., Xiong, X., Yang, H., Westland, C.E., Gibbs, C.S., Sarafianos, S.G. and Arnold, E., (2001), Molecular modeling and biochemical characterization reveal the mechanism of hepatitis B virus polymerase resistance to lamivudine (3TC) and emtricitabine (FTC). J Virol, 75, 4771–4779.

    PubMed  CAS  Google Scholar 

  • Davis, G.L., Wong, J.B., McHutchison, J.G., Manns, M.P., Harvey, J. and Albrecht, J., (2003), Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology, 38, 645–652.

    PubMed  CAS  Google Scholar 

  • de Franchis, R., Hadengue, A., Lau, G., Lavanchy, D., Lok, A., McIntyre, N., Mele, A., Paumgartner, G., Pietrangelo, A., Rodes, J., Rosenberg, W. and Valla, D., (2003), EASL International Consensus Conference on Hepatitis B. 13–14 September, 2002 Geneva, Switzerland. Consensus statement (long version). J Hepatol, 39 (Suppl. 1), S3–S25.

    PubMed  Google Scholar 

  • Delaney, W.E.t., Edwards, R., Colledge, D., Shaw, T., Furman, P., Painter, G. and Locarnini, S., (2002), Phenylpropenamide derivatives AT-61 and AT-130 inhibit replication of wild-type and lamivudine-resistant strains of hepatitis B virus in vitro. Antimicrob Agents Chemother, 46, 3057–3060.

    PubMed  CAS  Google Scholar 

  • Delaney, W.E.t., Edwards, R., Colledge, D., Shaw, T., Torresi, J., Miller, T.G., Isom, H.C., Bock, C.T., Manns, M.P., Trautwein, C. and Locarnini, S., (2001), Cross-resistance testing of antihepadnaviral compounds using novel recombinant baculoviruses which encode drug-resistant strains of hepatitis B virus. Antimicrob Agents Chemother, 45, 1705–1713.

    PubMed  CAS  Google Scholar 

  • Delaney, W.E.t., Ray, A.S., Yang, H., Qi, X., Xiong, S., Zhu, Y. and Miller, M.D., (2006), Intracellular metabolism and in vitro activity of tenofovir against hepatitis B virus. Antimicrob Agents Chemother, 50, 2471–2477.

    PubMed  CAS  Google Scholar 

  • Delaney, W.E.t., Yang, H., Westland, C.E., Das, K., Arnold, E., Gibbs, C.S., Miller, M.D. and Xiong, S., (2003), The hepatitis B virus polymerase mutation rtV173L is selected during lamivudine therapy and enhances viral replication in vitro. J Virol, 77, 11833–11841.

    PubMed  CAS  Google Scholar 

  • Dent, B., Chin, R., Trautwein, C., Bock, T.C., Manns, M.P., Cleary, D., Furman, P. and Locarnini, S.A., (2000), Antiviral cross-resistance profiles of two novel antiviral agents, DAPD and L-FMAU, against nucleoside analogue resistant HBV. Hepatology, 32 (Suppl. 1), 457A.

    Google Scholar 

  • Dienstag, J.L., Goldin, R.D., Heathcote, E.J., Hann, H.W., Woessner, M., Stephenson, S.L., Gardner, S., Gray, D.F. and Schiff, E.R., (2003), Histological outcome during long-term lamivudine therapy. Gastroenterology, 124, 105–117.

    PubMed  CAS  Google Scholar 

  • Dixit, N.M., Layden-Almer, J.E., Layden, T.J. and Perelson, A.S., (2004), Modelling how ribavirin improves interferon response rates in hepatitis C virus infection. Nature, 432, 922–924.

    PubMed  CAS  Google Scholar 

  • Duarte, E.A., Novella, I.S., Weaver, S.C., Domingo, E., Wain-Hobson, S., Clarke, D.K., Moya, A., Elena, S.F., de la Torre, J.C. and Holland, J.J., (1994), RNA virus quasispecies: significance for viral disease and epidemiology. Infect Agents Dis, 3, 201–214.

    PubMed  CAS  Google Scholar 

  • Durantel, D., Carrouee-Durantel, S., Werle-Lapostolle, B., Brunelle, M.N., Pichoud, C., Trepo, C. and Zoulim, F., (2004), A new strategy for studying in vitro the drug susceptibility of clinical isolates of human hepatitis B virus. Hepatology, 40, 855–864.

    PubMed  CAS  Google Scholar 

  • Eldrup, A.B., Allerson, C.R., Bennett, C.F., Bera, S., Bhat, B., Bhat, N., Bosserman, M.R., Brooks, J., Burlein, C., Carroll, S.S., Cook, P.D., Getty, K.L., MacCoss, M., McMasters, D.R., Olsen, D.B., Prakash, T.P., Prhavc, M., Song, Q., Tomassini, J.E. and Xia, J., (2004), Structure-activity relationship of purine ribonucleosides for inhibition of hepatitis C virus RNA-dependent RNA polymerase. J Med Chem, 47, 2283–2295.

    PubMed  CAS  Google Scholar 

  • Ferenci, P., Fried, M.W., Shiffman, M.L., Smith, C.I., Marinos, G., Goncales, F.L., Jr, Haussinger, D., Diago, M., Carosi, G., Dhumeaux, D., Craxi, A., Chaneac, M. and Reddy, K.R., (2005), Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin. J Hepatol, 43, 425–433.

    PubMed  CAS  Google Scholar 

  • Foy, E., Li, K., Sumpter, R., Jr., Loo, Y.M., Johnson, C.L., Wang, C., Fish, P.M., Yoneyama, M., Fujita, T., Lemon, S.M. and Gale, M., Jr., (2005), Control of antiviral defenses through hepatitis C virus disruption of retinoic acid-inducible gene-I signaling. Proc Natl Acad Sci USA, 102, 2986–2991.

    PubMed  CAS  Google Scholar 

  • Foy, E., Li, K., Wang, C., Sumpter, R., Jr., Ikeda, M., Lemon, S.M. and Gale, M., Jr., (2003), Regulation of interferon regulatory factor-3 by the hepatitis C virus serine protease. Science, 300, 1145–1148.

    PubMed  CAS  Google Scholar 

  • Frese, M., Pietschmann, T., Moradpour, D., Haller, O. and Bartenschlager, R., (2001), Interferon-alpha inhibits hepatitis C virus subgenomic RNA replication by an MxA-independent pathway. J Gen Virol, 82, 723–733.

    PubMed  CAS  Google Scholar 

  • Fried, M.W., Shiffman, M.L., Reddy, K.R., Smith, C., Marinos, G., Goncales, F.L., Jr, Haussinger, D., Diago, M., Carosi, G., Dhumeaux, D., Craxi, A., Lin, A., Hoffman, J. and Yu, J., (2002), Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med, 347, 975–982.

    PubMed  CAS  Google Scholar 

  • Fu, L. and Cheng, Y.C., (1998), Role of additional mutations outside the YMDD motif of hepatitis B virus polymerase in l(–)SddC (3TC) resistance. Biochem Pharmacol, 55, 1567–1572.

    PubMed  CAS  Google Scholar 

  • Fu, L. and Cheng, Y.C., (2000), Characterization of novel human hepatoma cell lines with stable hepatitis B virus secretion for evaluating new compounds against lamivudine- and penciclovir-resistant virus. Antimicrob Agents Chemother, 44, 3402–3407.

    PubMed  CAS  Google Scholar 

  • Gale, M., Jr, Blakely, C.M., Kwieciszewski, B., Tan, S.L., Dossett, M., Tang, N.M., Korth, M.J., Polyak, S.J., Gretch, D.R. and Katze, M.G., (1998), Control of PKR protein kinase by hepatitis C virus nonstructural 5A protein: molecular mechanisms of kinase regulation. Mol Cell Biol, 18, 5208–5218.

    PubMed  CAS  Google Scholar 

  • Gale, M., Jr and Foy, E.M., (2005), Evasion of intracellular host defence by hepatitis C virus. Nature, 436, 939–945.

    PubMed  CAS  Google Scholar 

  • Gale, M., Jr, Kwieciszewski, B., Dossett, M., Nakao, H. and Katze, M.G., (1999), Antiapoptotic and oncogenic potentials of hepatitis C virus are linked to interferon resistance by viral repression of the PKR protein kinase. J Virol, 73, 6506–6516.

    PubMed  CAS  Google Scholar 

  • Ganem, D. and Prince, A.M., (2004), Hepatitis B virus infection—natural history and clinical consequences. N Engl J Med, 350, 1118–1129.

    PubMed  CAS  Google Scholar 

  • Gintowt, A.A., Germer, J.J., Mitchell, P.S. and Yao, J.D., (2005), Evaluation of the MagNA Pure LC used with the Trugene HBV Genotyping Kit. J Clin Virol, 34, 155–157.

    PubMed  CAS  Google Scholar 

  • Gish, R.G., Leung, N.W., Wright, T.L., Trinh, H., Lang, W., Kessler, H.A., Fang, L., Wang, L.H., Delehanty, J., Rigney, A., Mondou, E., Snow, A. and Rousseau, F., (2002), Dose range study of pharmacokinetics, safety, and preliminary antiviral activity of emtricitabine in adults with hepatitis B virus infection. Antimicrob Agents Chemother, 46, 1734–1740.

    PubMed  CAS  Google Scholar 

  • Gopalsamy, A., Aplasca, A., Ciszewski, G., Park, K., Ellingboe, J.W., Orlowski, M., Feld, B. and Howe, A.Y., (2006), Design and synthesis of 3,4-dihydro-1H-[1]-benzothieno[2,3-c]pyran and 3,4-dihydro-1H-pyrano[3,4-b]benzofuran derivatives as non-nucleoside inhibitors of HCV NS5B RNA dependent RNA polymerase. Bioorg Med Chem Lett, 16, 457–460.

    PubMed  CAS  Google Scholar 

  • Gunther, S., Fischer, L., Pult, I., Sterneck, M. and Will, H., (1999), Naturally occurring variants of hepatitis B virus. Adv Virus Res, 52, 25–137.

    PubMed  CAS  Google Scholar 

  • Guo, J.T., Bichko, V.V. and Seeger, C., (2001), Effect of alpha interferon on the hepatitis C virus replicon. J Virol, 75, 8516–8523.

    PubMed  CAS  Google Scholar 

  • Hadziyannis, S.J., Sette, H., Jr, Morgan, T.R., Balan, V., Diago, M., Marcellin, P., Ramadori, G., Bodenheimer, H., Jr, Bernstein, D., Rizzetto, M., Zeuzem, S., Pockros, P.J., Lin, A. and Ackrill, A.M., (2004), Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med, 140, 346–355.

    PubMed  CAS  Google Scholar 

  • Hadziyannis, S.J., Tassopoulos, N.C., Heathcote, E.J., Chang, T.T., Kitis, G., Rizzetto, M., Marcellin, P., Lim, S.G., Goodman, Z., Ma, J., Brosgart, C.L., Borroto-Esoda, K., Arterburn, S. and Chuck, S.L., (2006), Long-term therapy with Adefovir Dipivoxil for HBeAg-negative chronic Hepatitis B for up to 5 years. Gastroenterology, 131, 1743–1751.

    PubMed  CAS  Google Scholar 

  • Hadziyannis, S.J., Tassopoulos, N.C., Heathcote, E.J., Chang, T.T., Kitis, G., Rizzetto, M., Marcellin, P., Lim, S.G., Goodman, Z., Wulfsohn, M.S., Xiong, S., Fry, J. and Brosgart, C.L., (2003), Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med, 348, 800–807.

    PubMed  CAS  Google Scholar 

  • He, Y., Nakao, H., Tan, S.L., Polyak, S.J., Neddermann, P., Vijaysri, S., Jacobs, B.L. and Katze, M.G., (2002), Subversion of cell signaling pathways by hepatitis C virus nonstructural 5A protein via interaction with Grb2 and P85 phosphatidylinositol 3-kinase. J Virol, 76, 9207–9217.

    PubMed  CAS  Google Scholar 

  • Heim, M.H., Moradpour, D. and Blum, H.E., (1999), Expression of hepatitis C virus proteins inhibits signal transduction through the Jak-STAT pathway. J Virol, 73, 8469–8475.

    PubMed  CAS  Google Scholar 

  • Hezode, C., Bouvier-Alias, M., Costentin, C., Medkour, F., Franc-Poole, E., Aalyson, M., Alam, J., Dhumeaux, D. and Pawlotsky, J.M., (2006), Effect of an IMPDH inhibitor, merimepodib (MMPD), assessed alone and in combination with ribavirin, on HCV replication: implications regarding ribavirin’s mechanism of action. Hepatology, 44 (Suppl. 2), 615A.

    Google Scholar 

  • Hinrichsen, H., Benhamou, Y., Wedemeyer, H., Reiser, M., Sentjens, R.E., Calleja, J.L., Forns, X., Erhardt, A., Cronlein, J., Chaves, R.L., Yong, C.L., Nehmiz, G. and Steinmann, G.G., (2004), Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients. Gastroenterology, 127, 1347–1355.

    PubMed  CAS  Google Scholar 

  • Hong, S.P., Kim, N.K., Hwang, S.G., Chung, H.J., Kim, S., Han, J.H., Kim, H.T., Rim, K.S., Kang, M.S., Yoo, W. and Kim, S.O., (2004), Detection of hepatitis B virus YMDD variants using mass spectrometric analysis of oligonucleotide fragments. J Hepatol, 40, 837–844.

    PubMed  CAS  Google Scholar 

  • Hultgren, C., Milich, D.R., Weiland, O. and Sallberg, M., (1998), The antiviral compound ribavirin modulates the T helper (Th) 1/Th2 subset balance in hepatitis B and C virus-specific immune responses. J Gen Virol, 79, 2381–2391.

    PubMed  CAS  Google Scholar 

  • Hussain, M., Fung, S., Libbrecht, E., Sablon, E., Cursaro, C., Andreone, P. and Lok, A.S., (2006), Sensitive line probe assay that simultaneously detects mutations conveying resistance to lamivudine and adefovir. J Clin Microbiol, 44, 1094–1097.

    PubMed  CAS  Google Scholar 

  • Kim, H.S., Han, K.H., Ahn, S.H., Kim, E.O., Chang, H.Y., Moon, M.S., Chung, H.J., Yoo, W., Kim, S.O. and Hong, S.P., (2005), Evaluation of methods for monitoring drug resistance in chronic hepatitis B patients during lamivudine therapy based on mass spectrometry and reverse hybridization. Antivir Ther, 10, 441–449.

    PubMed  CAS  Google Scholar 

  • Kim, J.L., Morgenstern, K.A., Lin, C., Fox, T., Dwyer, M.D., Landro, J.A., Chambers, S.P., Markland, W., Lepre, C.A., O’Malley, E.T., Harbeson, S.L., Rice, C.M., Murcko, M.A., Caron, P.R. and Thomson, J.A., (1996), Crystal structure of the hepatitis C virus NS3 protease domain complexed with a synthetic NS4A cofactor peptide. Cell, 87, 343–355.

    PubMed  CAS  Google Scholar 

  • Klumpp, K., Leveque, V., Le Pogam, S., Ma, H., Jiang, W.R., Kang, H., Granycome, C., Singer, M., Laxton, C., Hang, J.Q., Sarma, K., Smith, D.B., Heindl, D., Hobbs, C.J., Merrett, J.H., Symons, J., Cammack, N., Martin, J.A., Devos, R. and Najera, I., (2006), The novel nucleoside analog R1479 (4’-azidocytidine) is a potent inhibitor of NS5B-dependent RNA synthesis and hepatitis C virus replication in cell culture. J Biol Chem, 281, 3793–3799.

    PubMed  CAS  Google Scholar 

  • Koch, U. and Narjes, F., (2006), Allosteric inhibition of the hepatitis C virus NS5B RNA dependent RNA polymerase. Infect Disord Drug Targets, 6, 31–41.

    PubMed  CAS  Google Scholar 

  • Kukolj, G., McGibbon, G.A., McKercher, G., Marquis, M., Lefebvre, S., Thauvette, L., Gauthier, J., Goulet, S., Poupart, M.A. and Beaulieu, P.L., (2005), Binding site characterization and resistance to a class of non-nucleoside inhibitors of the hepatitis C virus NS5B polymerase. J Biol Chem, 280, 39260–39267.

    PubMed  CAS  Google Scholar 

  • Lai, C.L., Dienstag, J., Schiff, E., Leung, N.W., Atkins, M., Hunt, C., Brown, N., Woessner, M., Boehme, R. and Condreay, L., (2003), Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin Infect Dis, 36, 687–696.

    PubMed  CAS  Google Scholar 

  • Lai, C.L., Gane, E., Hsu, C.W., Thongsawat, S., Wang, Y., Chen, Y., Heathcote, E.J., Rasenack, J., Bzowej, N., Naoumov, N., Zeuzem, S., Di Bisceglie, A., Chao, G.C., Fielman-Constance, B.A. and Brown, N.A., (2006a), Two-year results from the GLOBE trial in patients with hepatitis B: greater clinical and antiviral efficacy for telbivudine (LdT) versus lamivudine. Hepatology, 44 (Suppl. 1), 222A.

    Google Scholar 

  • Lai, C.L., Gane, E., Liaw, Y.F., Thongsawat, S., Wang, Y., Chen, Y., Heathcote, E.J., Rasenack, J., Bzowej, N., Naoumov, N., Chao, G., Constance, B.F. and Brown, N.A., (2005), Maximal early HBV suppression is predictive of optimal virologic and clinical efficacy in nucleoside-treated hepatitis B patients: scientific observations from a large multinational trial (the GLOBE study). Hepatology, 42 (Suppl. 1), 232A.

    Google Scholar 

  • Lai, C.L., Shouval, D., Lok, A.S., Chang, T.T., Cheinquer, H., Goodman, Z., DeHertogh, D., Wilber, R., Zink, R.C., Cross, A., Colonno, R. and Fernandes, L., (2006b), Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med, 354, 1011–1020.

    CAS  Google Scholar 

  • Lampertico, P., (2006), Entecavir versus lamivudine for HBeAg positive and negative chronic hepatitis B. J Hepatol, 45, 457–460.

    PubMed  CAS  Google Scholar 

  • Lampertico, P., Marzano, A., Levrero, M., Santantonio, T., Di Marco, V., Brunetto, M., Andreone, P., Sagnelli, E., Fagiuoli, S., Mazzella, G., Raimondo, G., Gaeta, G. and Ascione, A., (2006), Adefovir and lamivudine combination therapy is superior to adefovir monotherapy for lamivudine-resistant patients with HBeAg-negative chronic hepatitis B. Hepatology, 44 (Suppl. 2), 693A.

    Google Scholar 

  • Lanford, R.E., Guerra, B., Lee, H., Averett, D.R., Pfeiffer, B., Chavez, D., Notvall, L. and Bigger, C., (2003), Antiviral effect and virus-host interactions in response to alpha interferon, gamma interferon, poly(I)-poly(C), tumor necrosis factor alpha, and ribavirin in hepatitis C virus subgenomic replicons. J Virol, 77, 1092–1104.

    PubMed  CAS  Google Scholar 

  • Lau, J.Y., Tam, R.C., Liang, T.J. and Hong, Z., (2002), Mechanism of action of ribavirin in the combination treatment of chronic HCV infection. Hepatology, 35, 1002–1009.

    PubMed  CAS  Google Scholar 

  • Lawitz, E., Nguyen, T., Younes, Z., Santoro, J., Gitlin, N., McEniry, D., Chasen, R., Goff, J., Knox, S., Kleber, K., Belanger, B., Brown, N.A. and Dieterich, D.T., (2006), Valopicitabine (NM283) plus peg-interferon in treatment-naive hepatitis C patients with HCV genotype 1 infection: HCV RNA clearance during 24 weeks of treatment. Hepatology, 44 (Suppl. 2), 223A.

    Google Scholar 

  • Le Pogam, S., Jiang, W.R., Leveque, V., Rajyaguru, S., Ma, H., Kang, H., Jiang, S., Singer, M., Ali, S., Klumpp, K., Smith, D., Symons, J., Cammack, N. and Najera, I., (2006), In vitro selected Con1 subgenomic replicons resistant to 2’-C-methyl-cytidine or to R1479 show lack of cross resistance. Virology, 351, 349–359.

    PubMed  CAS  Google Scholar 

  • Lee, W.M., (1997), Hepatitis B virus infection. N Engl J Med, 337, 1733–1745.

    PubMed  CAS  Google Scholar 

  • Leung, N.W., Lai, C.L., Chang, T.T., Guan, R., Lee, C.M. and Ng, K.Y., (2001), Extended lamivudine treatment inpatients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Hepatology, 33, 1527–1532.

    PubMed  CAS  Google Scholar 

  • Levine, S., Hernandez, D., Yamanaka, G., Zhang, S., Rose, R., Weinheimer, S. and Colonno, R.J., (2002), Efficacies of entecavir against lamivudine-resistant hepatitis B virus replication and recombinant polymerases in vitro. Antimicrob Agents Chemother, 46, 2525–2532.

    PubMed  CAS  Google Scholar 

  • Li, K., Foy, E., Ferreon, J.C., Nakamura, M., Ferreon, A.C., Ikeda, M., Ray, S.C., Gale, M., Jr and Lemon, S.M., (2005), Immune evasion by hepatitis C virus NS3/4A protease-mediated cleavage of the Toll-like receptor 3 adaptor protein TRIF. Proc Natl Acad Sci USA, 102, 2992–2997.

    PubMed  CAS  Google Scholar 

  • Liaw, Y.F., Chien, R.N., Yeh, C.T., Tsai, S.L. and Chu, C.M., (1999), Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy. Hepatology, 30, 567–572.

    PubMed  CAS  Google Scholar 

  • Liaw, Y.F., Sung, J.J., Chow, W.C., Farrell, G., Lee, C.Z., Yuen, H., Tanwandee, T., Tao, Q.M., Shue, K., Keene, O.N., Dixon, J.S., Gray, D.F. and Sabbat, J., (2004), Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med, 351, 1521–1531.

    PubMed  CAS  Google Scholar 

  • Lin, C., Gates, C.A., Rao, B.G., Brennan, D.L., Fulghum, J.R., Luong, Y.P., Frantz, J.D., Lin, K., Ma, S., Wei, Y.Y., Perni, R.B. and Kwong, A.D., (2005), In vitro studies of cross-resistance mutations against two hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061. J Biol Chem, 280, 36784–36791.

    PubMed  CAS  Google Scholar 

  • Lin, C., Lin, K., Luong, Y.P., Rao, B.G., Wei, Y.Y., Brennan, D.L., Fulghum, J.R., Hsiao, H.M., Ma, S., Maxwell, J.P., Cottrell, K.M., Perni, R.B., Gates, C.A. and Kwong, A.D., (2004), In vitro resistance studies of hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061: structural analysis indicates different resistance mechanisms. J Biol Chem, 279, 17508–17514.

    PubMed  CAS  Google Scholar 

  • Lindenbach, B.D., Evans, M.J., Syder, A.J., Wolk, B., Tellinghuisen, T.L., Liu, C.C., Maruyama, T., Hynes, R.O., Burton, D.R., McKeating, J.A. and Rice, C.M., (2005), Complete replication of hepatitis C virus in cell culture. Science, 309, 623–626.

    PubMed  CAS  Google Scholar 

  • Locarnini, S., Hatzakis, A., Heathcote, J., Keeffe, E.B., Liang, T.J., Mutimer, D., Pawlotsky, J.M. and Zoulim, F., (2004), Management of antiviral resistance in patients with chronic hepatitis B. Antivir Ther, 9, 679–693.

    PubMed  CAS  Google Scholar 

  • Lok, A.S., Heathcote, E.J. and Hoofnagle, J.H., (2001), Management of hepatitis B: 2000—summary of a workshop. Gastroenterology, 120, 1828–1853.

    PubMed  CAS  Google Scholar 

  • Lok, A.S., Lai, C.L., Leung, N., Yao, G.B., Cui, Z.Y., Schiff, E.R., Dienstag, J.L., Heathcote, E.J., Little, N.R., Griffiths, D.A., Gardner, S.D. and Castiglia, M., (2003), Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology, 125, 1714–1722.

    PubMed  CAS  Google Scholar 

  • Loo, Y.M., Owen, D.M., Li, K., Erickson, A.K., Johnson, C.L., Fish, P.M., Carney, D.S., Wang, T., Ishida, H., Yoneyama, M., Fujita, T., Saito, T., Lee, W.M., Hagedorn, C.H., Lau, D.T., Weinman, S.A., Lemon, S.M. and Gale, M., Jr., (2006), Viral and therapeutic control of IFN-beta promoter stimulator 1 during hepatitis C virus infection. Proc Natl Acad Sci USA, 103, 6001–6006.

    PubMed  CAS  Google Scholar 

  • Love, R.A., Parge, H.E., Wickersham, J.A., Hostomsky, Z., Habuka, N., Moomaw, E.W., Adachi, T. and Hostomska, Z., (1996), The crystal structure of hepatitis C virus NS3 proteinase reveals a trypsin-like fold and a structural zinc binding site. Cell, 87, 331–342.

    PubMed  CAS  Google Scholar 

  • Lu, L., Pilot-Matias, T.J., Stewart, K.D., Randolph, J.T., Pithawalla, R., He, W., Huang, P.P., Klein, L.L., Mo, H. and Molla, A., (2004), Mutations conferring resistance to a potent hepatitis C virus serine protease inhibitor in vitro. Antimicrob Agents Chemother, 48, 2260–2266.

    PubMed  CAS  Google Scholar 

  • Lutchman, G.A., Danehower, S., Park, Y., Ward, C., Liang, T.J., Hoofnagle, J.H., Thomson, M.Z. and Ghany, M.G., (2004), Mutation rate of hepatitis C virus in patients during ribavirin monotherapy. Hepatology, 40 (Suppl. 1), 385A.

    Google Scholar 

  • Macdonald, A., Crowder, K., Street, A., McCormick, C., Saksela, K. and Harris, M., (2003), The hepatitis C virus non-structural NS5A protein inhibits activating protein-1 function by perturbing ras-ERK pathway signaling. J Biol Chem, 278, 17775–17784.

    PubMed  CAS  Google Scholar 

  • Manns, M.P., McHutchison, J.G., Gordon, S.C., Rustgi, V.K., Shiffman, M., Reindollar, R., Goodman, Z.D., Koury, K., Ling, M. and Albrecht, J.K., (2001), Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358, 958–965.

    PubMed  CAS  Google Scholar 

  • Marcellin, P., Chang, T.T., Lim, S.G., Tong, M.J., Sievert, W., Shiffman, M.L., Jeffers, L., Goodman, Z., Wulfsohn, M.S., Xiong, S., Fry, J. and Brosgart, C.L., (2003), Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med, 348, 808–816.

    PubMed  CAS  Google Scholar 

  • Martell, M., Esteban, J.I., Quer, J., Genesca, J., Weiner, A., Esteban, R., Guardia, J. and Gomez, J., (1992), Hepatitis C virus (HCV) circulates as a population of different but closely related genomes: quasispecies nature of HCV genome distribution. J Virol, 66, 3225–3229.

    PubMed  CAS  Google Scholar 

  • McHutchison, J.G., Shiffman, M.L., Gordon, S.C., Lindsay, K.L., Morgan, T., Norkrans, G., Esteban-Mur, R., Poynard, T., Pockros, P.J., Albrecht, J.K. and Brass, C., (2006), Sustained virologic response (SVR) to interferon-alpha-2b +/– ribavirin therapy at 6 months reliably predicts long-term clearance of HCV at 5-year follow-up. J Hepatol, 44 (Suppl. 2), S275.

    Google Scholar 

  • Migliaccio, G., Tomassini, J.E., Carroll, S.S., Tomei, L., Altamura, S., Bhat, B., Bartholomew, L., Bosserman, M.R., Ceccacci, A., Colwell, L.F., Cortese, R., De Francesco, R., Eldrup, A.B., Getty, K.L., Hou, X.S., LaFemina, R.L., Ludmerer, S.W., MacCoss, M., McMasters, D.R., Stahlhut, M.W., Olsen, D.B., Hazuda, D.J. and Flores, O.A., (2003), Characterization of resistance to non-obligate chain-terminating ribonucleoside analogs that inhibit hepatitis C virus replication in vitro. J Biol Chem, 278, 49164–49170.

    PubMed  CAS  Google Scholar 

  • Mo, H., Lu, L., Pilot-Matias, T., Pithawalla, R., Mondal, R., Masse, S., Dekhtyar, T., Ng, T., Koev, G., Stoll, V., Stewart, K.D., Pratt, J., Donner, P., Rockway, T., Maring, C. and Molla, A., (2005), Mutations conferring resistance to a hepatitis C virus (HCV) RNA-dependent RNA polymerase inhibitor alone or in combination with an HCV serine protease inhibitor in vitro. Antimicrob Agents Chemother, 49, 4305–4314.

    PubMed  CAS  Google Scholar 

  • Murakami, E., Bao, H., Ramesh, M., McBrayer, T.R., Whitaker, T., Micolochick Steuer, H.M., Schinazi, R.F., Stuyver, L.J., Obikhod, A., Otto, M.J. and Furman, P.A., (2006), Mechanism of activation of beta-D-2’-deoxy-2’-fluoro-2’-C-methylcytidine and inhibition of hepatitis C virus NS5B RNA polymerase. Antimicrob Agents Chemother, 51, 503–509.

    PubMed  Google Scholar 

  • Neumann, A.U., Lam, N.P., Dahari, H., Gretch, D.R., Wiley, T.E., Layden, T.J. and Perelson, A.S., (1998), Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science, 282, 103–107.

    PubMed  CAS  Google Scholar 

  • Niesters, H.G., De Man, R.A., Pas, S.D., Fries, E. and Osterhaus, A.D., (2002), Identification of a new variant in the YMDD motif of the hepatitis B virus polymerase gene selected during lamivudine therapy. J Med Microbiol, 51, 695–699.

    PubMed  CAS  Google Scholar 

  • Nowak, M.A., Bonhoeffer, S., Hill, A.M., Boehme, R., Thomas, H.C. and McDade, H., (1996), Viral dynamics in hepatitis B virus infection. Proc Natl Acad Sci USA, 93, 4398–4402.

    PubMed  CAS  Google Scholar 

  • O’Brien, C., Godofsky, E., Rodriguez-Torres, M., Afdhal, N.H., Pappas, S.C., Pockros, P., Lawitz, E., Bzowej, N., Rustgi, V., Sulkowski, M.S., Sherman, K.E., Jacobson, I.M., Chao, G., Knox, S., Pietropaolo, K. and Brown, N.A., (2005), Randomized trial of valopicitabine (NM283), alone or with peginterferon, vs retreatment with peginterferon plus ribavirin in hepatitis C patients with previous non response to peginterferon-ribavirin: first interim results. Hepatology, 42 (Suppl. 1), 234A.

    Google Scholar 

  • Ono, S.K., Kato, N., Shiratori, Y., Kato, J., Goto, T., Schinazi, R.F., Carrilho, F.J. and Omata, M., (2001), The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance. J Clin Investig, 107, 449–455.

    PubMed  CAS  Google Scholar 

  • Osiowy, C., Villeneuve, J.P., Heathcote, E.J., Giles, E. and Borlang, J., (2006), Detection of rtN236T and rtA181V/T mutations associated with resistance to adefovir dipivoxil in samples from patients with chronic hepatitis B virus infection by the INNO-LiPA HBV DR line probe assay (version 2). J Clin Microbiol, 44, 1994–1997.

    PubMed  CAS  Google Scholar 

  • Pallier, C., Castera, L., Soulier, A., Hezode, C., Nordmann, P., Dhumeaux, D. and Pawlotsky, J.M., (2006a), Dynamics of hepatitis B virus resistance to lamivudine. J Virol, 80, 643–653.

    CAS  Google Scholar 

  • Pallier, C., Rodriguez, C., Brillet, R. and Pawlotsky, J.M., (2006b), Dynamics of hepatitis B virus resistance to adefovir dipivoxil unraveled by a thorough quasispecies analysis. Hepatology, 44 (Suppl. 2), 565A.

    Google Scholar 

  • Papatheodoridis, G.V., Dimou, E., Laras, A., Papadimitropoulos, V. and Hadziyannis, S.J., (2002), Course of virologic breakthroughs under long-term lamivudine in HBeAg-negative precore mutant HBV liver disease. Hepatology, 36, 219–226.

    PubMed  Google Scholar 

  • Pawlotsky, J.M., (2002), Molecular diagnosis of viral hepatitis. Gastroenterology, 122, 1554–1568.

    PubMed  CAS  Google Scholar 

  • Pawlotsky, J.M., (2003), Mechanisms of antiviral treatment efficacy and failure in chronic hepatitis C. Antiviral Res, 59, 1–11.

    PubMed  CAS  Google Scholar 

  • Pawlotsky, J.M., (2005a), Current and future concepts in hepatitis C therapy. Semin Liver Dis, 25, 72–83.

    Google Scholar 

  • Pawlotsky, J.M., (2005b), The concept of hepatitis B virus mutant escape. J Clin Virol, 34 (Suppl. 1), S125–S129.

    CAS  Google Scholar 

  • Pawlotsky, J.M., (2006a), Hepatitis C virus population dynamics during infection. Curr Top Microbiol Immunol, 299, 261–284.

    CAS  Google Scholar 

  • Pawlotsky, J.M., (2006b), Therapy of hepatitis C: from empiricism to eradication. Hepatology, 43, S207–S220.

    CAS  Google Scholar 

  • Pawlotsky, J.M., Dahari, H., Neumann, A.U., Hezode, C., Germanidis, G., Lonjon, I., Castera, L. and Dhumeaux, D., (2004), Antiviral action of ribavirin in chronic hepatitis C. Gastroenterology, 126, 703–714.

    PubMed  CAS  Google Scholar 

  • Pawlotsky, J.M. and Gish, R.G., (2006), Future therapies for hepatitis C. Antivir Ther, 11, 397–408.

    PubMed  CAS  Google Scholar 

  • Pawlotsky, J.M., Hezode, C., Pellegrin, B., Soulier, A., von Wagner, M., Brouwer, J.T., Missale, G., Germanidis, G., Lurie, Y., Negro, F., Esteban, J., Hellstrand, K., Ferrari, C., Zeuzem, S., Schalm, S.W. and Neumann, A.U., (2002), Early HCV genotype 4 replication kinetics during treatment with peginterferon alpha-2a (Pegasys)-ribavirin combination: a comparison with HCV genotypes 1 and 3 kinetics. Hepatology, 36, 291A.

    Google Scholar 

  • Pawlotsky, J.M. and McHutchison, J.G., (2004), Hepatitis C. Development of new drugs and clinical trials: promises and pitfalls. Summary of an AASLD hepatitis single topic conference, Chicago, IL, 27 February–1 March 2003. Hepatology, 39, 554–567.

    PubMed  Google Scholar 

  • Penin, F., (2003), Structural biology of hepatitis C virus. Clin Liver Dis, 7, 1–21.

    PubMed  Google Scholar 

  • Peters, M., (1996), Actions of cytokines on the immune response and viral interactions: an overview. Hepatology, 23, 909–916.

    PubMed  CAS  Google Scholar 

  • Polyak, S.J., Khabar, K.S., Paschal, D.M., Ezelle, H.J., Duverlie, G., Barber, G.N., Levy, D.E., Mukaida, N. and Gretch, D.R., (2001a), Hepatitis C virus nonstructural 5A protein induces interleukin-8, leading to partial inhibition of the interferon-induced antiviral response. J Virol, 75, 6095–6106.

    CAS  Google Scholar 

  • Polyak, S.J., Khabar, K.S., Rezeiq, M. and Gretch, D.R., (2001b), Elevated levels of interleukin-8 in serum are associated with hepatitis C virus infection and resistance to interferon therapy. J Virol, 75, 6209–6211.

    CAS  Google Scholar 

  • Poynard, T., Imbert-Bismut, F., Munteanu, M., Messous, D., Myers, R.P., Thabut, D., Ratziu, V., Mercadier, A., Benhamou, Y. and Hainque, B., (2004), Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCV FibroSure) and necrosis (ActiTest) in patients with chronic hepatitis C. Comp Hepatol, 3, 8.

    PubMed  Google Scholar 

  • Poynard, T., Imbert-Bismut, F., Munteanu, M. and Ratziu, V., (2005), FibroTest-FibroSURE: towards a universal biomarker of liver fibrosis? Expert Rev Mol Diagn, 5, 15–21.

    Google Scholar 

  • Reesink, H., Forestier, N., Weegink, C., Zeuzem, S., McNair, L., Purdy, M., Chu, H.M. and Jansen, P.L.M., (2006a), Initial results of a 14-day study of the hepatitis C virus inhibitor protease VX-950 in combination with peginterferon alpha-2a. J Hepatol, 44 (Suppl. 2), S272.

    Google Scholar 

  • Reesink, H.W., Zeuzem, S., Weegink, C.J., Forestier, N., van Vliet, A., van de Wetering de Rooij, J., McNair, L., Purdy, S., Kauffman, R., Alam, J. and Jansen, P.L., (2006b), Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study. Gastroenterology, 131, 997–1002.

    CAS  Google Scholar 

  • Reiser, M., Hinrichsen, H., Benhamou, Y., Reesink, H.W., Wedemeyer, H., Avendano, C., Riba, N., Yong, C.L., Nehmiz, G. and Steinmann, G.G., (2005), Antiviral efficacy of NS3-serine protease inhibitor BILN-2061 in patients with chronic genotype 2 and 3 hepatitis C. Hepatology, 41, 832–835.

    PubMed  CAS  Google Scholar 

  • Richman, D.D., (1996), The implications of drug resistance for strategies of combination antiviral chemotherapy. Antiviral Res, 29, 31–33.

    PubMed  CAS  Google Scholar 

  • Richman, D.D., (2000), The impact of drug resistance on the effectiveness of chemotherapy for chronic hepatitis B. Hepatology, 32, 866–867.

    PubMed  CAS  Google Scholar 

  • Richman, D.D., (2006), Contending with HBV resistance: lessons learned from HIV resistance and its management. Clinical Care Options, LLC, Atlanta, Georgia.

    Google Scholar 

  • Rodriguez-Torres, M., Lawitz, E., Muir, A.J., Keane, J., Kieffer, T.L., McNair, L. and McHutchison, J., (2006), Current status of subjects receiving peginterferon alfa-2a (PEG-IFN) and ribavirin (RBV) follow-on therapy after 28-day treatment with the hepatitis C protease inhibitor telaprevir (VX-950), PEG-IFN and RBV. Hepatology, 44 (Suppl. 2), 532A.

    Google Scholar 

  • Roque-Afonso, A.M., Ferey, M.P., Mackiewicz, V., Fki, L. and Dussaix, E., (2003), Monitoring the emergence of hepatitis B virus polymerase gene variants during lamivudine therapy in human immunodeficiency virus coinfected patients: performance of CLIP sequencing and line probe assay. Antivir Ther, 8, 627–634.

    PubMed  CAS  Google Scholar 

  • Sarrazin, C., Kieffer, T.L., Bartels, D., Hanzelka, B., Muh, U., Welker, M., Wincheringer, D., Zhou, Y., Chu, H.M., Lin, C., Weegink, C., Reesink, H., Zeuzem, S. and Kwong, A.D., (2007a), Dynamic HCV genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir (VX-950). Gastroenterology, 132, 1767–1777.

    CAS  Google Scholar 

  • Sarrazin, C., Rouzier, R., Wagner, F., Forestier, N., Larrey, D., Gupta, S., Hussain, M., Shah, A., Cutler, D., Zhang, J. and Zeuzem, S., (2007b), SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon-a2b for genotype 1 non-responders. Gastroenterology, 132, 1270–1278.

    CAS  Google Scholar 

  • Schildgen, O., Sirma, H., Funk, A., Olotu, C., Wend, U.C., Hartmann, H., Helm, M., Rockstroh, J.K., Willems, W.R., Will, H. and Gerlich, W.H., (2006), Variant of hepatitis B virus with primary resistance to adefovir. N Engl J Med, 354, 1807–1812.

    PubMed  CAS  Google Scholar 

  • Seigneres, B., Pichoud, C., Martin, P., Furman, P., Trepo, C. and Zoulim, F., (2002), Inhibitory activity of dioxolane purine analogs on wild-type and lamivudine-resistant mutants of hepadnaviruses. Hepatology, 36, 710–722.

    PubMed  CAS  Google Scholar 

  • Sertoz, R.Y., Erensoy, S., Pas, S., Akarca, U.S., Ozgenc, F., Yamazhan, T., Ozacar, T. and Niesters, H.G., (2005), Comparison of sequence analysis and INNO-LiPA HBV DR line probe assay in patients with chronic hepatitis B. J Chemother, 17, 514–520.

    PubMed  CAS  Google Scholar 

  • Severini, A., Liu, X.Y., Wilson, J.S. and Tyrrell, D.L., (1995), Mechanism of inhibition of duck hepatitis B virus polymerase by (–)-beta-L-2’,3’-dideoxy-3’-thiacytidine. Antimicrob Agents Chemother, 39, 1430–1435.

    PubMed  CAS  Google Scholar 

  • Shaw, T., Bartholomeusz, A. and Locarnini, S., (2006), HBV drug resistance: mechanisms, detection and interpretation. J Hepatol, 44, 593–606.

    PubMed  CAS  Google Scholar 

  • Sheldon, J., Camino, N., Rodes, B., Bartholomeusz, A., Kuiper, M., Tacke, F., Nunez, M., Mauss, S., Lutz, T., Klausen, G., Locarnini, S. and Soriano, V., (2005), Selection of hepatitis B virus polymerase mutations in HIV-coinfected patients treated with tenofovir. Antivir Ther, 10, 727–734.

    PubMed  CAS  Google Scholar 

  • Sherman, M., Yurdaydin, C., Sollano, J., Silva, M., Liaw, Y.F., Cianciara, J., Boron-Kaczmarska, A., Martin, P., Goodman, Z., Colonno, R., Cross, A., Denisky, G., Kreter, B. and Hindes, R., (2006), Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B. Gastroenterology, 130, 2039–2049.

    PubMed  CAS  Google Scholar 

  • Simmonds, P., Bukh, J., Combet, C., Deleage, G., Enomoto, N., Feinstone, S., Halfon, P., Inchauspe, G., Kuiken, C., Maertens, G., Mizokami, M., Murphy, D.G., Okamoto, H., Pawlotsky, J.M., Penin, F., Sablon, E., Shin, I.T., Stuyver, L.J., Thiel, H.J., Viazov, S., Weiner, A.J. and Widell, A., (2005), Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology, 42, 962–973.

    PubMed  CAS  Google Scholar 

  • Stuyver, L.J., Locarnini, S.A., Lok, A., Richman, D.D., Carman, W.F., Dienstag, J.L. and Schinazi, R.F., (2001), Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region. Hepatology, 33, 751–757.

    PubMed  CAS  Google Scholar 

  • Stuyver, L.J., McBrayer, T.R., Tharnish, P.M., Clark, J., Hollecker, L., Lostia, S., Nachman, T., Grier, J., Bennett, M.A., Xie, M.Y., Schinazi, R.F., Morrey, J.D., Julander, J.L., Furman, P.A. and Otto, M.J., (2006), Inhibition of hepatitis C replicon RNA synthesis by beta-D-2’-deoxy-2’-fluoro-2’-C-methylcytidine: a specific inhibitor of hepatitis C virus replication. Antivir Chem Chemother, 17, 79–87.

    PubMed  CAS  Google Scholar 

  • Sumpter, R., Jr., Loo, Y.M., Foy, E., Li, K., Yoneyama, M., Fujita, T., Lemon, S.M. and Gale, M., Jr., (2005), Regulating intracellular antiviral defense and permissiveness to hepatitis C virus RNA replication through a cellular RNA helicase, RIG-I. J Virol, 79, 2689–2699.

    PubMed  CAS  Google Scholar 

  • Tan, S.L., Nakao, H., He, Y., Vijaysri, S., Neddermann, P., Jacobs, B.L., Mayer, B.J. and Katze, M.G., (1999), NS5A, a nonstructural protein of hepatitis C virus, binds growth factor receptor-bound protein 2 adaptor protein in a Src homology 3 domain/ligand-dependent manner and perturbs mitogenic signaling. Proc Natl Acad Sci USA, 96, 5533–5538.

    PubMed  CAS  Google Scholar 

  • Taylor, D.R., Shi, S.T., Romano, P.R., Barber, G.N. and Lai, M.M., (1999), Inhibition of the interferon-inducible protein kinase PKR by HCV E2 protein. Science, 285, 107–110.

    PubMed  CAS  Google Scholar 

  • Tenney, D.J., Levine, S.M., Rose, R.E., Walsh, A.W., Weinheimer, S.P., Discotto, L., Plym, M., Pokornowski, K., Yu, C.F., Angus, P., Ayres, A., Bartholomeusz, A., Sievert, W., Thompson, G., Warner, N., Locarnini, S. and Colonno, R.J., (2004), Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine. Antimicrob Agents Chemother, 48, 3498–3507.

    PubMed  CAS  Google Scholar 

  • Tenney, D.J., Rose, R.E., Baldick, C.J., Levine, S.M., Pokornowski, K.A., Walsh, A.W., Fang, J., Yu, C.F., Zhang, S., Mazzucco, C.M., Eggers, B., Hsu, M., Plym, M.J., Poundstone, P., Yang, J. and Colonno, R.J., (2007), Two-year entecavir resistance assessment in lamivudine refractory HBV patients reveals different clinical outcomes depending on the resistance substitutions present. Antimicrob Agents Chemother, 51, 902–911.

    PubMed  CAS  Google Scholar 

  • Tilg, H., (1997), New insights into the mechanisms of interferon alfa: an immunoregulatory and anti-inflammatory cytokine. Gastroenterology, 112, 1017–1021.

    PubMed  CAS  Google Scholar 

  • Tomassini, J.E., Getty, K., Stahlhut, M.W., Shim, S., Bhat, B., Eldrup, A.B., Prakash, T.P., Carroll, S.S., Flores, O., MacCoss, M., McMasters, D.R., Migliaccio, G. and Olsen, D.B., (2005), Inhibitory effect of 2’-substituted nucleosides on hepatitis C virus replication correlates with metabolic properties in replicon cells. Antimicrob Agents Chemother, 49, 2050–2058.

    PubMed  CAS  Google Scholar 

  • Tomei, L., Altamura, S., Bartholomew, L., Biroccio, A., Ceccacci, A., Pacini, L., Narjes, F., Gennari, N., Bisbocci, M., Incitti, I., Orsatti, L., Harper, S., Stansfield, I., Rowley, M., De Francesco, R. and Migliaccio, G., (2003), Mechanism of action and antiviral activity of benzimidazole-based allosteric inhibitors of the hepatitis C virus RNA-dependent RNA polymerase. J Virol, 77, 13225–13231.

    PubMed  CAS  Google Scholar 

  • Tomei, L., Altamura, S., Bartholomew, L., Bisbocci, M., Bailey, C., Bosserman, M., Cellucci, A., Forte, E., Incitti, I., Orsatti, L., Koch, U., De Francesco, R., Olsen, D.B., Carroll, S.S. and Migliaccio, G., (2004), Characterization of the inhibition of hepatitis C virus RNA replication by nonnucleosides. J Virol, 78, 938–946.

    PubMed  CAS  Google Scholar 

  • Tong, X., Chase, R., Skelton, A., Chen, T., Wright-Minogue, J. and Malcolm, B.A., (2006), Identification and analysis of fitness of resistance mutations against the HCV protease inhibitor SCH 503034. Antiviral Res, 70, 28–38.

    PubMed  CAS  Google Scholar 

  • Tuttleman, J.S., Pourcel, C. and Summers, J., (1986), Formation of the pool of covalently closed circular viral DNA in hepadnavirus-infected cells. Cell, 47, 451–460.

    PubMed  CAS  Google Scholar 

  • van Bommel, F., Wunsche, T., Mauss, S., Reinke, P., Bergk, A., Schurmann, D., Wiedenmann, B. and Berg, T., (2004), Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection. Hepatology, 40, 1421–1425.

    PubMed  Google Scholar 

  • Villeneuve, J.P., Durantel, D., Durantel, S., Westland, C., Xiong, S., Brosgart, C.L., Gibbs, C.S., Parvaz, P., Werle, B., Trepo, C. and Zoulim, F., (2003), Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient. J Hepatol, 39, 1085–1089.

    PubMed  CAS  Google Scholar 

  • Villet, S., Pichoud, C., Villeneuve, J.P., Trepo, C. and Zoulim, F., (2006), Selection of a multiple drug-resistant hepatitis B virus strain in a liver-transplanted patient. Gastroenterology, 131, 1253–1261.

    PubMed  Google Scholar 

  • von Hahn, T., Evans, M.J., Syder, A.J., Hatziioannou, T., McKeating, J.A., Bieniasz, P.D. and Rice, C.M., (2006), Identification of claudin-1 as an essential cellular cell entry factor for hepatitis C virus. Hepatology, 44 (Suppl. 2), 197A.

    Google Scholar 

  • Wagoner, J., Austin, M., Green, J., Imaizumi, T., Casola, A., Brasier, A., Khabar, K.S., Wakita, T., Gale, M., Jr and Polyak, S.J., (2007), Regulation of CXCL-8 (interleukin-8) induction by double-stranded RNA signaling pathways during hepatitis C virus infection. J Virol, 81, 309–318.

    PubMed  CAS  Google Scholar 

  • Walters, K.A., Tipples, G.A., Allen, M.I., Condreay, L.D., Addison, W.R. and Tyrrell, L., (2003), Generation of stable cell lines expressing Lamivudine-resistant hepatitis B virus for antiviral-compound screening. Antimicrob Agents Chemother, 47, 1936–1942.

    PubMed  CAS  Google Scholar 

  • Westland, C., Delaney, W.t., Yang, H., Chen, S.S., Marcellin, P., Hadziyannis, S., Gish, R., Fry, J., Brosgart, C., Gibbs, C., Miller, M. and Xiong, S., (2003), Hepatitis B virus genotypes and virologic response in 694 patients in phase III studies of adefovir dipivoxil1. Gastroenterology, 125, 107–116.

    PubMed  CAS  Google Scholar 

  • Whalley, S.A., Murray, J.M., Brown, D., Webster, G.J., Emery, V.C., Dusheiko, G.M. and Perelson, A.S., (2001), Kinetics of acute hepatitis B virus infection in humans. J Exp Med, 193, 847–854.

    PubMed  CAS  Google Scholar 

  • Yamamoto, T., Litwin, S., Zhou, T., Zhu, Y., Condreay, L., Furman, P. and Mason, W.S., (2002), Mutations of the woodchuck hepatitis virus polymerase gene that confer resistance to lamivudine and 2’-fluoro-5-methyl-beta-L-arabinofuranosyluracil. J Virol, 76, 1213–1223.

    PubMed  CAS  Google Scholar 

  • Yan, Y., Li, Y., Munshi, S., Sardana, V., Cole, J.L., Sardana, M., Steinkuehler, C., Tomei, L., De Francesco, R., Kuo, L.C. and Chen, Z., (1998), Complex of NS3 protease and NS4A peptide of BK strain hepatitis C virus: a 2.2 A resolution structure in a hexagonal crystal form. Protein Sci, 7, 837–847.

    PubMed  CAS  Google Scholar 

  • Yang, H., Westland, C.E., Delaney, W.E.t., Heathcote, E.J., Ho, V., Fry, J., Brosgart, C., Gibbs, C.S., Miller, M.D. and Xiong, S., (2002), Resistance surveillance in chronic hepatitis B patients treated with adefovir dipivoxil for up to 60 weeks. Hepatology, 36, 464–473.

    PubMed  CAS  Google Scholar 

  • Yeon, J.E., Yoo, W., Hong, S.P., Chang, Y.J., Yu, S.K., Kim, J.H., Seo, Y.S., Chung, H.J., Moon, M.S., Kim, S.O., Byun, K.S. and Lee, C.H., (2006), Resistance to adefovir dipivoxil (ADV) in lamivudine-resistant chronic hepatitis B patients treated with ADV. Gut, 55, 1488–1495.

    PubMed  CAS  Google Scholar 

  • Yi, M., Tong, X., Skelton, A., Chase, R., Chen, T., Prongay, A., Bogen, S.L., Saksena, A.K., Njoroge, F.G., Veselenak, R.L., Pyles, R.B., Bourne, N., Malcolm, B.A. and Lemon, S.M., (2006), Mutations conferring resistance to SCH6, a novel hepatitis C virus NS3/4A protease inhibitor. Reduced RNA replication fitness and partial rescue by second-site mutations. J Biol Chem, 281, 8205–8215.

    PubMed  CAS  Google Scholar 

  • Ying, C., De Clercq, E. and Neyts, J., (2000), Lamivudine, adefovir and tenofovir exhibit long-lasting anti-hepatitis B virus activity in cell culture. J Viral Hepat, 7, 79–83.

    PubMed  CAS  Google Scholar 

  • Young, K.C., Lindsay, K.L., Lee, K.J., Liu, W.C., He, J.W., Milstein, S.L. and Lai, M.M., (2003), Identification of a ribavirin-resistant NS5B mutation of hepatitis C virus during ribavirin monotherapy. Hepatology, 38, 869–878.

    PubMed  CAS  Google Scholar 

  • Yuen, M.F., Kato, T., Mizokami, M., Chan, A.O., Yuen, J.C., Yuan, H.J., Wong, D.K., Sum, S.M., Ng, I.O., Fan, S.T. and Lai, C.L., (2003), Clinical outcome and virologic profiles of severe hepatitis B exacerbation due to YMDD mutations. J Hepatol, 39, 850–855.

    PubMed  CAS  Google Scholar 

  • Zoulim, F., (2004), Mechanism of viral persistence and resistance to nucleoside and nucleotide analogs in chronic hepatitis B virus infection. Antiviral Res, 64, 1–15.

    PubMed  CAS  Google Scholar 

  • Zoulim, F., Dannaoui, E., Borel, C., Hantz, O., Lin, T.S., Liu, S.H., Trepo, C. and Cheng, Y.C., (1996), 2’,3’-dideoxy-beta-L-5-fluorocytidine inhibits duck hepatitis B virus reverse transcription and suppresses viral DNA synthesis in hepatocytes, both in vitro and in vivo. Antimicrob Agents Chemother, 40, 448–453.

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. Jean-Michel Pawlotsky
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Infectious Disease, St. Michael’s Hospital, 30 Bond St., Suite 4179 Cardinal Carter Wing, Toronto, Ontario M5B 1W8, Canada

    I. W. Fong (Director) (Director)

  2. International Center for Public Health, 225 Warren Street, Newark, NJ 07103-3535, USA

    Karl Drlica

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Pawlotsky, JM. (2008). Hepatitis Virus Resistance. In: Fong, I.W., Drlica, K. (eds) Antimicrobial Resistance and Implications for the Twenty-First Century. Emerging Infectious Diseases of the 21st Century. Springer, Boston, MA. https://doi.org/10.1007/978-0-387-72418-8_9

Download citation

Publish with us

Policies and ethics

Search

Navigation